Asset Details
Do you wish to reserve the book?
Recognizing and treating secondary osteoporosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Recognizing and treating secondary osteoporosis
Do you wish to request the book?
Recognizing and treating secondary osteoporosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Recognizing and treating secondary osteoporosis
2012
Overview
Osteoporosis can be secondary to an underlying metabolic, nutritional, pharmacologic or disease-related cause; in such cases the triggering factor should be identified and treated. Approaches to the identification and management of patients with secondary osteoporosis are outlined in this Review, alongside mechanistic insights into the bone pathology.
Osteoporosis, through its association with fragility fracture, is a major public health problem, costing an estimated $34.8 billion worldwide per annum. With projected demographic changes, the burden looks set to grow. Therefore, the prevention of osteoporosis, as well as its identification and treatment once established, are becoming increasingly important. Osteoporosis is secondary when a drug, disease or deficiency is the underlying cause. Glucocorticoids, hypogonadism, alcohol abuse and malnutrition are among the most frequently recognized causes of secondary osteoporosis but the list of implicated diseases and drugs is growing and some of the more recently recognized associations, such as those with haematological conditions and acid-suppressing medications, are less well publicized. In some cases, advancement in treatment of the primary disease has led to people living long enough to develop secondary osteoporosis; for example, successful treatment for breast and prostate malignancies by hormonal manipulation, improved survival in HIV with the advent of anti-retroviral therapies, and improved treatment for cystic fibrosis. This Review emphasizes the importance of secondary osteoporosis, discusses familiar and less well-known causes and what is known of their mechanisms, provides guidance as to the pragmatic identification of secondary osteoporosis and summarizes treatment options, where available.
Key Points
Osteoporosis and associated fragility fractures are major public health problems, but once fractures develop, it is already too late; thus, prevention is a priority
A growing number of diseases, deficiencies and drugs are recognised as causing secondary osteoporosis, and should be suspected as causes in particular among men and pre-menopausal women presenting with osteoporosis
In most cases, the general principle of treatment of secondary osteoporosis is to treat the underlying disease or deficiency, or to remove the relevant drug
Mechanisms of secondary osteoporosis vary and include low bone mass, increasing falls, and reduced bone quality—treatment strategies might need to be adapted for different patients
Publisher
Nature Publishing Group UK,Nature Publishing Group
